Type 2 Diabetes | Treatment Algorithms: Claims Data Analysis | US | 2017
Historically, biguanides and sulfonylureas were the most heavily prescribed T2D drug classes. However, the DPP-IV inhibitors have recently overtaken sulfonylureas to become the second-most heavily prescribed drug class. Numerous branded agents jostle for position as second-line treatment options, including the DPP-IV inhibitors, the SGLT2inhibitors Jardiance, Invokana and Farxiga, the GLP-1 receptor agonists Victoza and Trulicity, and the insulins. Adding to the complexity of the market dynamics, the biosimilar insulin Basaglar is also picking up significant patient share.
Questions answered:
What patient share do key therapies and brands garner by line of therapy in newly diagnosed type 2 diabetes patients? What are the quarterly trends in prescribing among recently-treated and new diagnosed type 2 diabetes patients?
What proportion of type 2 diabetes patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
What percentage of type 2 diabetes patients are treated with monotherapy versus combination therapy? What are the most widely used combination therapies?
What are the product-level compliance and persistency rates among drug-treated patients with type 2 diabetes?
Key analysis provided:
Brand usage across longitudinal patient sample
Newly diagnosed patient analysis
Treatment initiation and progression
Line of therapy analysis
Combination therapy analysis
Source of business for recently treated patients
Persistency and compliance analysis
Product-level patient flow charts
Markets covered: United States
Primary research: Longitudinal patient-level claims data analysis